Can鈥檛 see the audio player?聽
KHN correspondent Shefali Luthra joined a discussion on the Vox podcast 鈥淭oday, Explained鈥 about the cost dynamics surrounding pre-exposure prophylaxis, or PrEP, a game-changing drug that prevents the transmission of HIV.
Gilead Sciences 鈥 the manufacturer of the brand-name versions of this preventive medicine, such as Truvada and Descovy 鈥 seeks to extend its patent but faces pushback from federal lawmakers, including Sen. Bernie Sanders (I-Vt.) and Rep. Alexandria Ocasio-Cortez (D-N.Y.).
Luthra has reported on how public health officials whose efforts to increase access to the HIV prevention pill for those at risk have faced roadblocks: the drug鈥檚 price tag, which has surged in recent years, and changes in insurance coverage that put a heftier financial burden on patients.
麻豆女优 Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at 麻豆女优鈥攁n independent source of health policy research, polling, and journalism. Learn more about .